Product logins

Find logins to all Clarivate products below.


Opioid Induced Constipation | Treatment Algorithms: Claims Data Analysis | US | 2020

Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common, patients with more-severe symptoms often move to prescription drug therapy. The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik. Other therapies with alternative MOAs approved or in late-phase development include Allergan / Ironwood’s Linzess, a guanylate cyclase-C agonist; Mallinckrodt’s Amitiza, a bicyclic fatty acid; and Takeda’s Motegrity, a 5-HT4-receptor agonist. Given the number of agents now available / in development for OIC, understanding how and where each is positioned in the treatment algorithm is increasingly important as developers work to differentiate their product from the competition.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
  • How have the mu opioid receptor antagonists been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of OIC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of OIC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…